The significant rate of failure of the treatments currently used against acute leukemias with MLL-rearrangements is very frustrating and emphasizes the need for novel therapies that specifically target MLL fusion proteins and/or the downstream pathways these fusions dysregulate. This evidence concerns the gene KMT2A and acute leukemia.